Owen 1991.

Methods	Randomisation: Two randomisation lists were made with 20 women on each list and block randomised into blocks of four. Allocation Concealment: method unclear Blinding: double‐blind Trial design: Parallel. Analysis: No power calculation or intention to treat analysis performed. Study setting: single centre, location London. Withdrawals: none (<10%). Cancelled Cycles: <10%.
Participants	Number of women:n= 25 (13 growth hormone, 12 placebo). Inclusion criteria: one or more previous IVF cycles with poor response, defined as fewer than six oocytes retrieved from which fewer than three embryos developed. Cause of subfertility: 18 of 25 women found to have polycystic ovaries on ultrasound. Age: <38
Interventions	Intervention: growth hormone 24 IU intramuscular (IM), days 1, 3, 5, 7, 9, and 11 of hMG treatment, during long GnRHa protocol, vs placebo given IM on same cycle days as active treatment groups. Dose of human chorionic gonadotropin: 5000 IU
Outcomes	Live birth rate, pregnancy rate, adverse effects (multiple pregnancy and ectopic pregnancy).
Notes	Nature of placebo not described. Follicular fluid IG1 increased by 27% with growth hormone treatment. The data from Jacobs 1995 is also presented in Owen 1991.
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Low risk	Two randomisation lists were made with 20 women on each list and block randomised into blocks of four
Allocation concealment?	Unclear risk	Not stated within the text
Blinding? All outcomes	Low risk	Double blinded
Free of selective reporting?	Low risk	There is no indication the study has reported outcomes selectively
Free of other bias?	High risk	Nature of placebo not described. Follicular fluid IG1 increased by 27% with growth hormone treatment